# Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

> **NCT00832234** · PHASE2 · COMPLETED · sponsor: **European Myeloma Network B.V.** · enrollment: 59 (actual)

## Conditions studied

- Waldenstroms Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib, Dexamethasone, Rituximab

## Key facts

- **NCT ID:** NCT00832234
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2010-06
- **Final completion:** 2013-06
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2015-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832234, "Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00832234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*